All In Biotech

Free tool

FAERS Monitor: Actimmune

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 103836 or its brand name (Actimmune, Interferon Gamma-1b). Reports on generic versions are filed under their own applications.

Reports

1,409

Serious

918

65% of reports

Hospitalization

548

Death reported

204

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pyrexia193
  • off label use178
  • pneumonia102
  • influenza like illness92
  • fatigue68
  • death63
  • headache61
  • chills55
  • malaise51
  • pain49
  • nausea48
  • dyspnoea47
  • infection41
  • vomiting40
  • hospitalisation37

Reports by year received

View as table
YearReports
2004113
200582
2006110
200762
200819
20099
201011
20115
20122
20138
201479
2015238
2016215
201764
201846
201998
202062
202125
202240
202331
202442
202522
202626

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,750 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
influenza like illnessSignal9216.713.71,346
pyrexiaSignal1938.37.31,258
chillsSignal557.05.4279
pneumoniaSignal1024.73.9298
infectionSignal414.23.199
hospitalisationSignal373.62.667
off label useSignal1783.02.6251
malaise511.71.316
headache611.51.18
fatigue681.31.05
vomiting401.30.92
dyspnoea471.20.92
pain491.20.91
death631.10.90
nausea480.90.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.